Business Context and Reporting Period
Company: IRIDEX Corporation (IRIX)
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2025
Reporting Period: The filing addresses a compliance notice received on May 14, 2025, based on financial data from the quarterly period ended March 29, 2025.
Key Financial Metrics
- Stockholders' Equity: Approximately $852,000 as of March 29, 2025.
- Minimum Equity Requirement: $2,500,000 (Nasdaq Listing Rule 5550(b)(1)).
- Recent Capital Raise: $6,000,000 proceeds from the sale of Series B Preferred Stock in March 2025.
- Equity Classification: The Series B Preferred Stock is currently classified as "temporary equity," excluding it from the stockholders' equity calculation for listing purposes.
- Revenue/Profit/Cash Flow: The filing text does not provide specific values for revenue, profit, or cash flow for the current period.
Material Changes and Compliance Status
The Company received a notification of non-compliance from Nasdaq regarding the minimum stockholders' equity requirement. The Company's reported equity of $852,000 falls significantly short of the $2,500,000 threshold. Additionally, the Company does not meet alternative listing requirements based on market value of listed securities or net income from continuing operations.
The non-compliance is primarily driven by the accounting classification of the Series B Preferred Stock sold in March 2025. Because this instrument is classified as "temporary equity," the $6,000,000 in proceeds does not count toward the stockholders' equity requirement.
Outlook, Management Commentary, and Risks
- Remediation Plan: The Company is seeking stockholder approval at its annual meeting on June 11, 2025, to amend its Certificate of Incorporation (the "Restated Charter Proposal"). This amendment aims to reclassify the Series B Preferred Stock as "permanent equity," which would restore compliance with the $2,500,000 equity requirement.
- Timeline: The Company intends to submit a Compliance Plan to Nasdaq by June 30, 2025 (within 45 days of the notice). If accepted, Nasdaq may grant a cure period of up to 180 days.
- Trading Status: The common stock will continue to be listed and traded on the Nasdaq Capital Market during the cure period, subject to the acceptance of the Compliance Plan.
- Risks: There is no assurance that stockholders will approve the Restated Charter Proposal, that Nasdaq will accept the Compliance Plan, or that the Company will regain compliance. Failure to comply could result in delisting.
Investor Verification Checklist
- Verify the outcome of the stockholder vote on the Restated Charter Proposal at the June 11, 2025 annual meeting.
- Confirm whether Nasdaq accepts the Company's Compliance Plan by the June 30, 2025 deadline.
- Monitor the reclassification of Series B Preferred Stock from "temporary equity" to "permanent equity" in subsequent financial filings.
- Review the Definitive Proxy Statement filed on April 28, 2025, for details on the Restated Charter and voting procedures.